Brought to you by 
Deciphera funds clinical work with $185.9mm public offering
06 Jul 2018
Executive Summary
Oncology drug development company Deciphera Pharmaceuticals Inc. netted $185.9mm through its first public offering since its September 2017 IPO. The company sold 4.9mm common shares (including the overallotment) at $40, and intends to use the majority of the proceeds ($100mm) to fund continued development of lead candidate DCC2618, which is in Phase III trials as a fourth-line treatment for gastrointestinal stromal tumors (GIST) and earlier trials for additional advanced cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Deciphera funds clinical work with $185.9mm public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice